{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-005048","form_type":"8-K","ticker":"CORT","cik":"0001088856","company_name":"CORCEPT THERAPEUTICS INC","filed_at":"2024-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.333048+00:00","generated_at":"2026-06-06T00:43:01.972887+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Corcept Q4 revenue $135.4M (+31% YoY); reiterates FY2024 guidance $600-630M","bullets":["Q4 revenue $135.4M (+31% YoY); net income $31.4M ($0.28 diluted EPS) vs $16.6M in Q4 2022.","Full-year 2023 revenue $482.4M (+20% YoY); net income $106.1M ($0.94 diluted EPS).","Cash and investments $425.4M; 2024 revenue guidance reiterated at $600-$630M.","NDA for relacorilant in Cushing's expected Q2 2024; GRACE results Q2; CATALYST shows 24% hypercortisolism prevalence in first 700 patients.","ROSELLA ovarian cancer trial and DAZALS ALS trial results expected by year-end 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-005048","json":"https://secwatch.observer/filing/0001628280-24-005048.json","markdown":"https://secwatch.observer/filing/0001628280-24-005048.md","text":"https://secwatch.observer/filing/0001628280-24-005048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1088856/000162828024005048/0001628280-24-005048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1088856/000162828024005048/cort-20240215.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T00:43:01.972887+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"95dcee43cd90348b5d7f7b0a1b3eb6ac5c07259c","claim":"CORCEPT THERAPEUTICS INC reported the quarter and year ended December 31, 2023 results: revenue $135.4 million, net income $31.4 million, EPS $0.28. Guidance reaffirmed.","evidence_excerpt":"today reported its results for the quarter and year ended December 31, 2023. Financial Results • Fourth quarter revenue of $135.4 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1088856/000162828024005048/0001628280-24-005048-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2023"},{"label":"Revenue","value":"$135.4 million"},{"label":"Net income","value":"$31.4 million"},{"label":"EPS","value":"$0.28"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"b6df668dd2968799a0774cb62266c7aa2f7157f7","claim":"CORCEPT THERAPEUTICS INC reported the year ended December 31, 2023 results: revenue $482.4 million, net income $106.1 million, EPS $0.94. Guidance reaffirmed.","evidence_excerpt":"and year ended December 31, 2023. Financial Results • Fourth quarter revenue of $135.4 million, a 31 percent increase over the same period in 2022 • Full year 2023 revenue of $482.4 million, a 20 percent increase over 2022 • Reiterated 2024 revenue guidance of $600 – $630 million • Fourth quarter net income of $31.4 million, compared to $16.6 million in fourth","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1088856/000162828024005048/0001628280-24-005048-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Revenue","value":"$482.4 million"},{"label":"Net income","value":"$106.1 million"},{"label":"EPS","value":"$0.94"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}